83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2
View the complete AFFIRM study description.
The specific mechanism(s) by which TYSABRI exerts its effects in relapsing MS have not been fully defined.1
In demyelinating diseases such as MS, evidence suggests α4-integrin may play a key role in inhibiting CNS migration of lymphocytes—a trigger in the inflammatory process in MS. TYSABRI is a monoclonal antibody that may help control inflammatory activity in MS through inhibition of α4-integrin.1,3
CNS=central nervous system.
TYSABRI is a 1-hour IV infusion administered once every 28 days.1
Remember: Only orders from infusion centers and certified pharmacies enrolled in and authorized by the TOUCH® Prescribing Program will be processed. Contact Biogen at 1-800-456-2255.
In the AFFIRM trial, a 2-year, multicenter, double-blind, placebo-controlled study in 942 patients with relapsing MS, TYSABRI significantly reduced1,2:
aDefined as an increase of ≥1.0 point on the EDSS from baseline EDSS ≥1.0 that was sustained for 12 weeks, or a ≥1.5-point increase on the EDSS from a baseline EDSS of 0 that was sustained for 12 weeks.1
Gd+=gadolinium-enhancing; EDSS=Expanded Disability Status Scale.
PML=progressive multifocal leukoencephalopathy; JCV=John Cunningham Virus.
Before prescribing TYSABRI, ask your patients if they are pregnant or plan to become pregnant. It is not known if TYSABRI can harm fetal development; there are no adequate data on the risk associated with the use of TYSABRI in pregnant women. Natalizumab has been detected in human milk. There are no data on the effects of this exposure on the breastfed infant or the effects of the drug on milk production.
Please see full Prescribing Information.
When cost may be a concern for your patients, Biogen is here to help them start and continue on TYSABRI.
We will work with your patients based on their individual needs. Biogen Support Services offers a variety of different financial and insurance resources, including:
Help Your Patients Get Support
Your patients can call 1-800-456-2255 Monday-Friday from 8:30 AM to 8 PM ET. Hablamos español.
bEffective January 1, 2021, there is an annual cap on the amount of assistance that patients can receive over a one-year period. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. You are eligible to enroll in the Biogen Copay Program for as long as it is offered and you are treated with a Biogen relapsing MS medication. The Biogen Copay Program is no longer available for TECFIDERA patients in the states of Massachusetts and California.
Biogen, the company behind TYSABRI, has spent more than 20 years developing treatments for people with relapsing MS. For the most information, your patients can visit our patient-friendly website—TYSABRI.com.
Remind your patients that Biogen Support Coordinators are available to assist with any questions or concerns. Patients can call 1-800-456-2255, Monday through Friday from 8:30 AM to 8:00 PM ET
AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting Multiple Sclerosis.